📈 Finance & Markets
Today's top 5 stories, curated by Daily Direct.
Three AI stocks are flashing buy signals as Q2 gets underway, with valuations sitting at levels that may not last long. The window for picking them up at a discount is narrowing as investor appetite for AI plays remains strong. Missing the entry point now could mean paying a significantly higher price later.
Read article →Allbirds, the struggling sustainable footwear brand, saw its stock surge over 600% after announcing a pivot to artificial intelligence — a dramatic rebranding that has more to do with market sentiment than sneakers. The move follows a familiar playbook of companies chasing AI euphoria to revive flagging valuations. Whether the rebrand signals a genuine strategic shift or a desperate bid for relevance remains the defining question for investors.
Read article →Morgan Stanley delivered a blowout quarter, with trading revenue surpassing Wall Street estimates by $1 billion on the back of surging fixed income and equities activity. The firm's trading operations alone generated $8.5 billion in revenue, underscoring the outsized role markets volatility has played in boosting top-tier bank earnings. The results reinforce Morgan Stanley's position as one of the dominant forces in global trading.
Read article →BlackRock posted a 46% jump in first-quarter profit to $2.12 billion, signaling robust demand for the world's largest asset manager's products and services. The surge underscores investor confidence returning to markets despite ongoing macroeconomic uncertainty. For the asset management industry, the result sets a bullish tone heading into the rest of the year.
Read article →Eli Lilly has surged ahead of Novo Nordisk in the race to dominate the booming weight loss drug market, with its valuation trajectory signaling a commanding lead in what analysts project could become a trillion-dollar industry. The gap between the two pharma giants has widened as Lilly's pipeline and commercial execution outpace its Danish rival. For Novo Nordisk, the pressure is mounting to deliver its next generation of treatments before Lilly locks in the market.
Read article →Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →